Gastroparesis Lawsuits in 2026: 4,025 GLP-1 Cases, the 3.67x Study, and the Proof 75% of Claims Must Show

As of October 1, 2026, 4,025 lawsuits over gastrointestinal injuries from GLP-1 drugs are pending in federal multidistrict litigation in Philadelphia, most alleging gastroparesis — stomach paralysis. No case has settled and none has gone to trial; a September 2026 expert hearing will decide whether most claims survive.

Key facts

  • 4,025 actions are pending in MDL 3094 (U.S. District Court for the Eastern District of Pennsylvania, Judge Karen S. Marston), with 4,139 total filed, per the Judicial Panel on Multidistrict Litigation's October 1, 2026 statistics report.
  • About 75% of complaints allege gastroparesis or stomach paralysis, 18% allege ileus (intestinal blockage), and 8% allege gallbladder injuries.
  • An October 2023 JAMA study (Sodhi et al., JAMA 2023;330(18):1795–1797, PMID 37796527) found weight-loss GLP-1 users faced 3.67 times the risk of gastroparesis, 4.22 times the risk of bowel obstruction, and 9.09 times the risk of pancreatitis.
  • The FDA added ileus to Ozempic's label in November 2023.
  • A Rule 702 expert hearing ran September 14–18, 2026, with closing arguments October 13; no ruling has issued, no bellwether trial schedule exists, and no settlement has been announced. Any per-person settlement figure you see online is invented.

For the broader litigation picture, see our October 2026 Ozempic lawsuit status update, and follow developments on our video channel Problem Solved.

What Gastroparesis Claims Actually Allege

A GLP-1 receptor agonist is a drug that mimics a natural gut hormone, slowing digestion and lowering blood sugar. That slowed digestion is the intended effect. The lawsuits allege that for some patients, the slowing does not stop at a comfortable pace: the stomach slows to the point of paralysis. Gastroparesis is the medical term for a stomach that empties far too slowly or stops moving food into the small intestine — producing persistent vomiting, severe nausea, abdominal pain, and sometimes hospitalization.

The legal claim is not that the drugs never work; it is failure to warn. Plaintiffs argue the manufacturers — Novo Nordisk for Ozempic, Wegovy and Rybelsus (semaglutide); Eli Lilly for Trulicity (dulaglutide) and Mounjaro (tirzepatide) — did not adequately warn patients and prescribers that slowed digestion could become stomach paralysis.

The 3.67x Study at the Center of the Science Fight

The most-cited evidence is an October 2023 study by Sodhi and colleagues in JAMA (JAMA 2023;330(18):1795–1797, PMID 37796527). Comparing weight-loss GLP-1 users against users of a different weight-loss drug, it found 3.67 times higher gastroparesis risk, 4.22 times higher bowel-obstruction risk, and 9.09 times higher pancreatitis risk.

These are relative risks, not absolute ones — they multiply a baseline that is small for most people. Both sides interpret them differently: plaintiffs read a clear safety signal; the manufacturers dispute that association proves causation in any individual case. In April 2026, a separate large review of clinical data reinforced that gastrointestinal injuries, including stomach paralysis and bowel obstruction, are among the most consistently reported side effects of GLP-1 drugs.

The FDA's November 2023 Label Change — and Its Limits

In November 2023, the FDA updated Ozempic's labeling to mention ileus — a temporary intestinal blockage. The update did not add gastroparesis to the label, and the manufacturers point to that gap. Plaintiffs counter that the relevant question is what a reasonable warning required when they were taking the drugs — in 2021, 2022, or earlier — not what regulators had added by late 2023.

MDL 3094 by the Numbers

Multidistrict litigation is the federal procedure that consolidates cases sharing common facts before a single judge for pretrial proceedings — here, Judge Karen S. Marston in the Eastern District of Pennsylvania. The October 1, 2026 JPML statistics report counts 4,025 actions pending, with 4,139 filed in total — more than double the roughly 1,800 pending in August 2025.

Two tracks matter. The gastrointestinal cases — MDL 3094 — cover Ozempic, Wegovy and Rybelsus, plus Trulicity and Mounjaro. A separate proceeding, MDL 3163, handles NAION vision-loss claims (247 actions pending) and involves a different drug list. Our separate coverage explains the Ozempic vision-loss claims and the Ozempic ileus claims.

The September 2026 Hearing That Decides Everything

A Rule 702 hearing — sometimes called a Daubert hearing — is where the judge decides whether expert testimony is scientifically reliable enough for a jury. Judge Marston held a multi-day hearing September 14–18, 2026 on the plaintiffs' general-causation experts; closing arguments were heard October 13. No ruling has issued. If the experts survive, the litigation proceeds toward bellwether trials (none scheduled); if excluded, most claims cannot prove causation.

Under the court's Case Management Order 32 (April 30, 2026), the court already requires objective diagnostic testing for gastroparesis claims — a medical documentation standard, not a marketing promise.

What a Qualifying Case Actually Needs

A viable gastroparesis claim generally needs documented use of one of the covered GLP-1 drugs, a diagnosis supported by objective testing, and records tying the injury to the drug period — emergency or hospital records, prescription histories, and a physician's assessment. Law-firm marketing lists broader criteria; the court's orders are stricter, and they are what count.

The Honest Bottom Line

No GLP-1 gastroparesis case has settled, none has gone to verdict, and no bellwether trial has been scheduled. Anyone quoting you a per-person amount is inventing it. What exists is a 4,025-case federal litigation, a peer-reviewed study, a pending expert-evidence ruling, and status conferences on November 17 and December 15, 2026 — which will tell you more than any advertisement.

This article is general information, not legal advice. Lawsuit outcomes depend on individual facts, and only a qualified attorney can evaluate a claim.

Who Benefits From This — and Who Does Not

With 4,025 cases pending and no settlement or trial yet, a gastroparesis claim today is a bet on proof: the files that survive will be the documented ones.

Who benefits:

  • Patients with a documented gastroparesis diagnosis after GLP-1 use: Diagnosis plus contemporaneous treatment records are the core of a qualifying case. How: gather prescribing records, diagnosis records, and treatment history before speaking to a lawyer.
  • Claimants who understand the September 2026 hearing: That expert hearing decides whether most claims survive. How: follow the hearing’s outcome before judging the strength of any individual file.
  • Patients whose records show the drugs named in the litigation: The MDL covers the GLP-1 gastrointestinal claims described in this article. How: confirm your prescribed drug and dates against the litigation’s scope.

Who benefits little or not at all:

  • Anyone expecting a settlement payout now: No case has settled and none has gone to trial — there is no payout to claim yet.
  • Claimants without diagnosis or records: A prescription alone does not prove gastroparesis, and the JAMA study’s relative risks are interpreted differently by both sides on causation.
  • People whose symptoms have another documented cause: If the records point elsewhere, the causation evidence the hearing tests will work against the claim.

Related reading: Ozempic Lawsuit Update October 2026: 4,025 Cases, the Rule 702 Hearing, and What It Means for Your Claim.

Frequently Asked Questions

How many GLP-1 gastroparesis lawsuits are pending in 2026?

4,025 actions were pending in MDL 3094 as of October 1, 2026, according to the Judicial Panel on Multidistrict Litigation, with 4,139 filed in total. About 75% of the complaints allege gastroparesis or stomach paralysis.

Has there been an Ozempic gastroparesis settlement?

No. As of October 2026, no GLP-1 gastrointestinal case has settled, no case has gone to verdict, and no bellwether trial has been scheduled. Any per-person settlement figure published online is invented.

What proof do gastroparesis claims need?

Under the court's Case Management Order 32, gastroparesis claims require objective diagnostic testing, plus documented use of a covered GLP-1 drug and medical records tying the injury to the drug period.

Which drugs are included in the GLP-1 gastrointestinal litigation?

MDL 3094 covers Ozempic, Wegovy and Rybelsus (semaglutide, Novo Nordisk), Trulicity (dulaglutide) and Mounjaro (tirzepatide, Eli Lilly). Vision-loss claims are in a separate MDL with a different drug list.

What did the JAMA study actually find?

The October 2023 Sodhi study found weight-loss GLP-1 users had 3.67 times the gastroparesis risk, 4.22 times the bowel-obstruction risk, and 9.09 times the pancreatitis risk versus users of another weight-loss drug — relative risks, which both sides interpret differently on causation.

Who benefits from a GLP-1 gastroparesis claim — and who does not?

Patients with a documented gastroparesis diagnosis after GLP-1 use, backed by prescribing and treatment records, benefit most — though with 4,025 cases pending and no settlement or trial yet, no payout exists today. Claimants without a diagnosis or records benefit little, and anyone expecting an immediate settlement will be disappointed: the September 2026 expert hearing decides whether most claims survive at all.

Watch on YouTube

Problem Solved on YouTube